Table 1.
Comparison of baseline clinical characteristics for the High and Low ALBI groups.
| High ALBI Group (n = 109) | Low ALBI Group (n = 71) | p Value | |
|---|---|---|---|
| Age | 67.2 ± 11.5 | 66.7 ± 10.9 | 0.770 |
| Male (n, %) | 77 (70.6%) | 50 (70.4%) | 0.975 |
| Body mass index, kg/cm2 | 22.2 ± 3.6 | 22.5 ± 3.6 | 0.529 |
| Systolic blood pressure, mmHg | 102.0 (94.0–112.0) | 109.0 (96.0–118.0) | 0.030 |
| Diastolic blood pressure, mmHg | 60.0 (56.0–68.0) | 63.0 (59.0–70.0) | 0.068 |
| Heart rate, bpm | 65.9 ± 15.4 | 63.3 ± 14.9 | 0.266 |
| NYHA class III/IV (n, %) | 46 (42.2%) | 17 (23.9%) | 0.012 |
| Ischemic etiology (n, %) | 26 (23.8%) | 10 (14.0%) | 0.109 |
| Hypertension (n, %) | 68 (62.3%) | 41 (57.7%) | 0.534 |
| Diabetes (n, %) | 59 (54.1%) | 32 (45.0%) | 0.235 |
| Chronic kidney disease (n, %) | 76 (69.7%) | 52 (73.2%) | 0.611 |
| Atrial fibrillation (n, %) | 30 (27.5%) | 13 (18.3%) | 0.157 |
| QRS duration >150 ms (n, %) | 70 (64.2%) | 48 (67.6%) | 0.640 |
| LBBB morphology (n, %) | 60 (55.0%) | 44 (61.9%) | 0.358 |
| Implantation for secondary prevention (n, %) | 39 (35.7%) | 24 (33.8%) | 0.786 |
| Atrioventricular block requiring a pacemaker (n, %) | 24 (22.4%) | 12 (16.9%) | 0.369 |
| Medication | |||
| β blockers (n, %) | 109 (100.0%) | 68 (95.7%) | 0.060 |
| ACE-Inhibitors/ARBs (n, %) | 91 (83.4%) | 59 (83.0%) | 0.946 |
| Mineralocorticoid receptor antagonists (n, %) | 69 (63.3%) | 52 (73.2%) | 0.165 |
| Amiodarone (n, %) | 66 (60.5%) | 36 (50.7%) | 0.193 |
| Inotropic agents (n, %) | 51 (46.7%) | 16 (22.5%) | 0.001 |
ACE-inhibitors: angiotensin-converting enzyme-inhibitors; ARBs: angiotensin II receptor blockers; NYHA: New York Heart Association; LBBB: left bundle branch block.